<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, who had been unresponsive to <z:chebi fb="5" ids="50113">androgens</z:chebi>, antithymocyte globulin, high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>, and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, responded to treatment with 3-beta-<z:chebi fb="0" ids="28195">etiocholanolone</z:chebi>, <z:chebi fb="0" ids="7466">nandrolone</z:chebi> <z:chebi fb="0" ids="27689">decanoate</z:chebi>, and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Six months following initiation of therapy, she became red cell and platelet transfusion independent with neutrophils persistently over 1,000/microliters </plain></SENT>
<SENT sid="2" pm="."><plain>A sustained partial remission has persisted for over 2 years </plain></SENT>
<SENT sid="3" pm="."><plain>This observation suggests that a combined hematostimulatory approach may be of benefit, even in patients with long-standing refractory <z:mpath ids='MPATH_58'>aplasia</z:mpath> </plain></SENT>
</text></document>